Document Registry

Home
About DPP
Contact
DPP Protocol
DPP OS Protocol
Manuals
Timeline
Slides
Publications
News archive
Program Staff

Study Documents Web Site

Registry of Published Manuscripts

01/01/03 The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003 Jan;26(1)36-47.

12/02/02 The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care. 2002 Dec;25(12):2165-71.

11/01/02 Delahanty LM, Meigs JB, Hayden D, Williamson DA, Nathan DM, and the DPP Research Group. Psychological and behavioral correlates of baseline BMI in the Diabetes Prevention Program (DPP). Diabetes Care. 2002 Nov;25(11):1992-8.

04/01/03 The Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care. 2003 Apr;26(4):977-80.

05/15/03 Molitch M, Fujimoto W, Hamman R, Knowler W for the Diabetes Prevention Program Research Group. The Diabetes Prevention Program and its global implications (Singapore paper). J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S103-7.

11/14/02 The Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002 Nov;40(5)679-86.

08/01/02 Wylie-Rosette J, Delahanty L. An integral role of the dietitian: Implications of the Diabetes Prevention Program. J Am Diet Assoc. 2002 Aug;102(8):1065-8.

04/01/97 Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettit DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF. Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies. Diabetes. 1997 Apr;46(4):701-10.

04/01/99 The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999 Apr;22(4):623-34.

11/01/00 The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Baseline characteristics of the randomized cohort. Diabetes Care. 2000 Nov;23(11):1619-29.

02/07/02 The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6);393-403.

04/01/02 The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Recruitment methods and results. Control Clin Trials. 2002 Apr;23(2):157-71.

04/01/00 Fujimoto WY. Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care. 2000 Apr;23 Suppl 2:B11-3.

10/01/99 The Diabetes Prevention Program Research Group. Response to Adler, Turner, Singer et al. Diabetes Care. 1999 Oct;22(10):1757-8.

06/06/02 Knowler W for the Diabetes Prevention Program Research Group. Response to Bo-abbas, Brousseau, Louria, Benjamin et al. N Engl J Med. 2002 Jun 6;346(23):1829-30.

09/01/03 The Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003 Sep;26(9):2518-23.

09/01/03 Molitch M. for the Diabetes Research Group. Response to Scheen and Buchaan. Diabetes Care. 2003 Sep;26(9):2702-3.

09/26/04 Mayer-Davis EJ, Sparks KC, Hirst K, Costacou T, Lovejoy JC, Regensteiner JG, Hoskin M, Kriska AM, Bray G and the Diabetes Prevention Program Research Group. Dietary intake in the Diabetes Prevention Program cohort: Baseline and 1-year post-randomization. Ann Epidemiol. 2004 Nov;14(10):763-72.

09/01/04 The Diabetes Prevention Program Research Group. Achieving weight and activity goals among Diabetes Prevention Program lifestyle participants. Obes Res. 2004 Sep;12(9):1426-34.

01/01/05 The Diabetes Prevention Program Research Group. Strategies to identify adults at high risk for type 2 diabetes. Diabetes Care. 2005 Jan;28(1):138-44.

03/01/05 Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE for the Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005 Mar;142(5):323-32.

04/01/05 The Diabetes Prevention Program Research Group. Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care. 2005 Apr;28(4):830-7.

04/01/05 The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005 Apr;28(4):888-94.

04/01/05 The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr;54(4):1150-6.

04/19/05 Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research Group. The effect of metformin and lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med. 2005 Apr 19;142(8):611-19.

05/01/05 Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005 May;54(5):1566-72.

08/01/05 The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: Effects of lifestyle intervention and metformin. Diabetes. 2005 Aug;54(8):2404-14.

10/04/05 The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the Diabetes Prevention Program. Diabetes Care. 2005 Oct;28(10):2472-9.

02/01/06 Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y, Vittinghoff E, Kanaya AM for the Diabetes Prevention Program Research Group. Lifestyle intervention is associated with lower prevalence of urinary incontinence: The Diabetes Prevention Program. Diabetes Care. 2006 Feb;29(2):385-90.

12/01/05 Hoskin M, Begay S, Bolin P, Hermes J, Ingraham L, Killean T, Nelson J, Percy C, Scurlock N, Shovestull LE, Tomchee C, the Diabetes Prevention Program and Action for Health in Diabetes (Look AHEAD) research groups. Providing lifestyle interventions in American Indian communities. Obesity Management Journal 2005 Dec;1(6):251-5.

03/28/06 Ratner R for the Diabetes Prevention Program Research Group. An Update on the Diabetes Prevention Program. Endocr Prac. 2006 Jan-Feb;12 Suppl 1:20-4.

04/01/06 Carnethon MR, Prineas RJ, Temprosa M, Zhang Z, Uwaifo G, Molitch ME for the Diabetes Prevention Program Research Group. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006 Apr;29(4):914-9.

05/01/06 Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, Wing RR, Horton ES, Haffner SM, Regensteiner JG. Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. Med Sci Sports Exerc. 2006 May;38(5):826-32.

05/01/06 Delahanty LM, Conroy MB, Nathan DM, and the Diabetes Prevention Program Research Group. Psychological predictors of physical activity in the Diabetes Prevention Program. J Am Diet Assoc. 2006 May;106(5):698-705.

07/20/06 Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PIW, Shuldiner AR, Knowler WC, Nathan DM and Altshuler D for the Diabetes Prevention Program Research Group. TCF7L2 Polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006 Jul 20;355(3):241-50.

09/01/06 Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, Smith K, Johnson MK, Kitabchi A, Crandall J, for the Diabetes Prevention Program Research Group. Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care. 2006 Sept;29(9):1997-2002.

09/01/06 Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J, for the Diabetes Prevention Program Research Group. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006 Sep;29(9):2102-7.

11/30/06 The Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the Diabetes Prevention Program. Obesity. 2006 Nov;14(11):2107-17.

10/31/06 The Diabetes Prevention Program Research Group. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1075-81.

02/01/07 Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan CM and Altshuler D for the Diabetes Prevention Program Research Group. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007 Feb;56(2):531-6.

01/26/07 The Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007 Feb;24(2):137-44.

01/07/07 Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM and Altshuler D for the Diabetes Prevention Program Research Group. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab. 2007;92(4):doi:10.1210/jc.2006-2275.

06/01/07 The Diabetes Prevention Program Research Group. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program (DPP). Diabetes. 2007 Jun;56:1680-5.

04/01/07 Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM for the Diabetes Prevention Program Research Group. Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes. 2007 Apr;56:1153-59

10/01/07 Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E for the Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007 Oct;30(10):2453-7.

12/01/07 Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC for the Diabetes Prevention Program Research Group. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia. 2007 Dec;50(12):2451-60.

12/04/07 Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, Barroso I, Franks PW, Altshuler D, Knowler WC for the Diabetes Prevention Program. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia. 2007 Dec 4;51:451-7.

03/01/08 Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, Price DW, Knowler WC for the Diabetes Prevention Program Research Group. Elevated Depression Symptoms, Antidepressant Medicine Use and Risk of Developing Diabetes during the Diabetes Prevention Program. Diabetes Care. 2008 Mar;31(3):420-6.

01/11/08 Mather K, Funahashi T, Matsuzawa Y, Edelstein S, Bray G, Kahn S, Crandall J, Marcovina S, Goldstein B, Goldberg R for the DPP Research Group. Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes. 2008 Apr;57:980-6.